fda warning letter semaglutide october 2025 Drug compounders sue over declaration ending Wegovy shortage FDA Decisions Expected: October 2025

NIH describes the cardiovascular implications as uncertain but concerning enough to discuss with a clinician if you have heart disease risk, high LDL cholesterol, kidney disease, or plan to use high doses for months

Adding berberine to any regimen containing such medications can raise their plasma concentrations and produce unexpected side effects

Check for any cloudiness, particles, or color changes that were not present before the exposure

Understanding these potential adverse reactions enables early recognition and appropriate management

the schedule shows minimum intervals and an ordered sequence, but the decision to hold, advance, or pause belongs to the clinician who knows your tolerability and goals

Designed to bypass digestion This delivery method is designed to avoid breakdown in the gut and liver, supporting efficient use of each dose